✦ LIBER ✦

A Phase II trial of gemcitabine for metastatic neuroendocrine tumors

✍ Scribed by Matthew H. Kulke; Haesook Kim; Jeffrey W. Clark; Peter C. Enzinger; Thomas J. Lynch; Jeffrey A. Morgan; Michele Vincitore; Ann Michelini; Charles S. Fuchs

Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 77 KB
Volume: 101
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.20466

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

BACKGROUND

Treatment with traditional cytotoxic chemotherapy regimens containing streptozocin or dacarbazine has resulted in only marginal benefit for patients with metastatic neuroendocrine tumors. The use of these regimens has been further limited by their potential toxicity. Gemcitabine is generally well tolerated and possesses demonstrated activity against a wide range of malignancies. The authors assessed the efficacy of gemcitabine in the treatment of patients with metastatic neuroendocrine tumors.

METHODS

Eighteen patients with metastatic neuroendocrine tumors were treated with gemcitabine administered on a standard weekly schedule. Patients were followed for evidence of toxicity, response, and survival.

RESULTS

Gemcitabine was well tolerated. However, no radiologic or biochemical responses were observed. Although the majority of patients (65%) experienced disease stabilization as their best response to therapy, the overall median survival duration was only 11.5 months.

CONCLUSIONS

📜 SIMILAR VOLUMES

A phase II trial of biweekly high dose g

A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma

✍ Herbert Ulrich-Pur; Gabriela V. Kornek; Markus Raderer; Karin Haider; Werner Kwa 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 2 views

Paclitaxel, carboplatin, and gemcitabine

Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma : A Phase II trial using a triplet combination

✍ Swan-Swan Leong; Joseph Wee; Miah Hiang Tay; Chee Keong Toh; Say Beng Tan; Choon 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB

Flexible chemotherapy regimen with gemci

Flexible chemotherapy regimen with gemcitabine and vinorelbine for metastatic nonsmall cell lung carcinoma : A Phase II multicenter trial

✍ Vera Hirsh; Adrian Langleben; Joseph Ayoub; Yvon Cormier; Javier Pintos; José L. 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 2 views

A phase II trial of taxol in metastatic

A phase II trial of taxol in metastatic melanoma

✍ Sewa S. Legha; Sigrid Ring; Nicholas Papadopoulos; Martin Raber; Robert S. Benja 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 321 KB 👁 2 views

Weekly paclitaxel and gemcitabine chemot

Weekly paclitaxel and gemcitabine chemotherapy for metastatic non-small cell lung carcinoma (NSCLC) : A dose-optimizing phase II trial

✍ Vera Hirsh; Renaud Whittom; Linda Ofiara; Pierre Desjardins; Joseph Ayoub; Danie 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB 👁 2 views

## Abstract ## BACKGROUND The current dose‐optimizing Phase II study evaluated the effect of weekly paclitaxel and gemcitabine on the response rate and survival of patients with non‐small cell lung carcinoma (NSCLC) using dose modifications that permitted optimal treatment intensity. ## METHODS

Expanded phase II trial of gemcitabine a

Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer

✍ Rachel P. Riechelmann; Carol A. Townsley; Sheray N. Chin; Gregory R. Pond; Jenni 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 2 views

## Abstract ## BACKGROUND. A phase 2 trial of gemcitabine and capecitabine (GemCap) in patients with advanced biliary cancer led to an objective response in approximately 30% of patients and a median survival of 14 months. In the current study, the authors report further efficacy data of a larger